Cost-effectiveness of a Transplantation Strategy Compared to Melphalan and Prednisone in Younger Patients with Multiple Myeloma

C. Tom Kouroukis Department of Hematology-Oncology, Cancer Care Ontario, Hamilton Regional Cancer Centre, 699 Concession Street, Hamilton, Ontario, Canada, L8V 5C2; Hamilton Health Sciences, Henderson Campus, 711 Concession Street, Hamilton, Ontario, Canada, L8V 1C3; Department of Medicine, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada, L8N 3Z5Correspondence[email protected]; E-mail: [email protected]

Bernie J. O'brien Centre for Evaluation of Medicines, St. Joseph's Healthcare, 50 Charlton Ave. East, Hamilton, Ontario, Canada, L8N 4A6; Department of Clinical Epidemiology and Biostatistics, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada, L8N 3Z5

Ann Benger Department of Hematology-Oncology, Cancer Care Ontario, Hamilton Regional Cancer Centre, 699 Concession Street, Hamilton, Ontario, Canada, L8V 5C2; Hamilton Health Sciences, Henderson Campus, 711 Concession Street, Hamilton, Ontario, Canada, L8V 1C3; Department of Medicine, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada, L8N 3Z5

Deborah Marcellus Department of Hematology-Oncology, Cancer Care Ontario, Hamilton Regional Cancer Centre, 699 Concession Street, Hamilton, Ontario, Canada, L8V 5C2; Hamilton Health Sciences, Henderson Campus, 711 Concession Street, Hamilton, Ontario, Canada, L8V 1C3; Department of Medicine, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada, L8N 3Z5

Ronan Foley Hamilton Health Sciences, Henderson Campus, 711 Concession Street, Hamilton, Ontario, Canada, L8V 1C3; Department of Medicine, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada, L8N 3Z5; Department of Pathology, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada, L8N 3Z5

Jane Garner Hamilton Health Sciences, Henderson Campus, 711 Concession Street, Hamilton, Ontario, Canada, L8V 1C3

Carol Ingram Hamilton Health Sciences, Henderson Campus, 711 Concession Street, Hamilton, Ontario, Canada, L8V 1C3

Patricia Haines Clinical Trials Department, Cancer Care Ontario, Hamilton Regional Cancer Centre, 699 Concession Street, Hamilton, Ontario, Canada, L8V 5C2

Nancy Henderson-O'connor Hamilton Health Sciences, Henderson Campus, 711 Concession Street, Hamilton, Ontario, Canada, L8V 1C3

Ralph Meyer Department of Hematology-Oncology, Cancer Care Ontario, Hamilton Regional Cancer Centre, 699 Concession Street, Hamilton, Ontario, Canada, L8V 5C2; Hamilton Health Sciences, Henderson Campus, 711 Concession Street, Hamilton, Ontario, Canada, L8V 1C3; Department of Medicine, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada, L8N 3Z5

show all

Abstract

High dose chemotherapy with autologous stem cell transplantation (ASCT) improves outcomes in patients 65 years of age or less with multiple myeloma. Survival and costs in a cohort of 16 patients who received melphalan and prednisone as part of a clinical trial were compared with those of 36 patients referred to our centre for consideration of ASCT. In the transplant group, survival and costs were extrapolated to match the period of observation in the melphalan and prednisone group. Patient-specific and average costs were calculated from the perspective of the Ontario Ministry of Health. Costs and survival were varied by 50% in the sensitivity analysis. Transplantation improved life expectancy by 19.3 months with a cost difference of $30,517 Canadian. The incremental cost-effectiveness of transplantation compared with melphalan and prednisone was $25,710 Canadian per life-year gained when additional pamidronate and follow-up costs were considered. Discounting costs and survival at 3 and 5% did not result in important differences. The sensitivity analysis resulted in best and worse case scenarios for transplantation compared with melphalan and prednisone of $13,049 and $63,954 per life-year gained respectively. In comparison with melphalan and prednisone, ASCT appears to be cost-effective in patients 65 years old or younger with myeloma.

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Cost-effectiveness of a Transplantation Strategy Compared to Melphalan and Prednisone in Younger Patients with Multiple Myeloma

Information for

Open access

Opportunities

Help and information

Cost-effectiveness of a Transplantation Strategy Compared to Melphalan and Prednisone in Younger Patients with Multiple Myeloma

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature